Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease
Oncogene addiction in non-small-cell lung cancer (NSCLC) has profound diagnostic and therapeutic implications. ALK, ROS1 and NTRK rearrangements are found in about 2–7%, 1–2% and 0.2% of unselected NSCLC samples, respectively; however, their frequency is markedly higher in younger and never-smoker p...
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Article |
| Langue: | English |
| Publié: |
BioExcel Publishing Ltd
2022-10-01
|
| Collection: | Drugs in Context |
| Sujets: | |
| Accès en ligne: | https://www.drugsincontext.com/non-small-cell-lung-cancer-how-to-manage-alk-ros1-and-ntrk-rearranged-disease |